Meeting
2016 ASCO Annual Meeting
18-FLT-PET/CT as an imaging biomarker in patients with ASS1-deficient thoracic cancers treated with ADI-PEG20, pemetrexed and cisplatin.
Authors
Peter Wojciech Szlosarek
St Bartholomew's Hospital, London, United Kingdom
Peter Wojciech Szlosarek , Teresa Szyszko , Simon Pacey , James F. Spicer , Melissa Phillips , Jeremy P. C. Steele , Adalberto Barba , Monica Diaz , Amanda Johnston , Bor-Wen Wu , John S. Bomalaski , Gary J. R. Cook
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Clinical Trial Registration Number
NCT02029690
Citation
J Clin Oncol 34, 2016 (suppl; abstr 11567)
DOI
10.1200/JCO.2016.34.15_suppl.11567
Abstract #
11567
Poster Bd #
264
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Expansion study of ADI-PEG 20, pemetrexed and cisplatin in patients with ASS1-deficient malignant pleural mesothelioma (TRAP).
First Author: Melissa Phillips
Poster
2015 ASCO Annual Meeting
Phase I study of ADI-PEG 20 in combination with pemetrexed and cisplatin (TRAP) in patients with ASS1-deficient mesothelioma and non-squamous lung cancer.
First Author: Peter Wojciech Szlosarek
Poster
2019 ASCO Annual Meeting
Phase 1 dose-expansion study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1 (ASS1)–deficient non-squamous non-small cell lung cancer.
First Author: Akhila Ganeshi Wimalasingham
Poster
2018 ASCO Annual Meeting
SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma.
First Author: Anne S. Tsao